The Experts below are selected from a list of 2505 Experts worldwide ranked by ideXlab platform
Hans H. Stærfeldt - One of the best experts on this subject based on the ideXlab platform.
-
A scored human protein-protein interaction network to catalyze genomic interpretation.
Nature methods, 2016Co-Authors: Rasmus Wernersson, Rasmus B. Hansen, Johnathan Mercer, Greg Slodkowicz, Kristoffer Rapacki, Heiko Horn, Olga Rigina, Christopher T Workman, Hans H. StærfeldtAbstract:Genome-scale human protein-protein interaction networks are critical to understanding cell biology and interpreting genomic data, but challenging to produce experimentally. Through data integration and quality control, we provide a scored human protein-protein interaction network (InWeb_InBioMap, or InWeb_IM) with severalfold more interactions (>500,000) and better functional biological relevance than comparable resources. We illustrate that InWeb_InBioMap enables functional interpretation of >4,700 cancer genomes and genes involved in autism.
-
A scored human protein-protein interaction network to catalyze genomic interpretation
Nature Methods, 2016Co-Authors: Taibo Li, Rasmus B. Hansen, Johnathan Mercer, Greg Slodkowicz, Kristoffer Rapacki, Heiko Horn, Olga Rigina, Rasmus Wernersson, Christopher T Workman, Hans H. StærfeldtAbstract:Human protein-protein interaction networks are critical to understanding cell biology and interpreting genetic and genomic data, but are challenging to produce in individual large-scale experiments. We describe a general computational framework that through data integration and quality control provides a scored human protein-protein interaction network (InWeb\_IM). Juxtaposed with five comparable resources, InWeb\_IM has 2.8 times more interactions (~585K) and a superior functional signal showing that the added interactions reflect real cellular biology. InWeb_IM is a versatile resource for accurate and cost-efficient functional interpretation of massive genomic datasets illustrated by annotating candidate genes from >4,700 cancer genomes and genes involved in neuropsychiatric diseases.
Alexander Kapp - One of the best experts on this subject based on the ideXlab platform.
-
exacerbation of atopic dermatitis on grass pollen exposure in an environmental challenge chamber
The Journal of Allergy and Clinical Immunology, 2015Co-Authors: Thomas Werfel, Margarete Niebuhr, Lennart M Roesner, Annika Karch, Christian Losche, Annice Heratizadeh, Alexander Kapp, Veit J. Erpenbeck, Thomas Jung, Norbert KrugAbstract:Background It has frequently been speculated that pruritus and skin lesions develop after topical exposure to aeroallergens in sensitized patients with atopic dermatitis (AD). Objective We sought to study cutaneous reactions to grass pollen in adult patients with AD with accompanying clear IgE sensitization to grass allergen in an environmental challenge chamber using a monocenter, double-blind, placebo-controlled study design. Methods Subjects were challenged on 2 consecutive days with either 4000 pollen grains/m 3 of Dactylis glomerata pollen or clean air. The severity of AD was assessed at each study visit up to 5 days after challenge by (objective) scoring of AD (SCORAD). Additionally, air-exposed and non–air-exposed skin areas were each scored using local SCORAD scoring and investigator global assessments. Levels of a series of serum cytokines and chemokines were determined by using a Luminex-based immunoassay. The primary end point of the study was the change in objective SCORAD scores between prechallenge and postchallenge values. Results Exposure to grass pollen induced a significant worsening of AD. A pronounced eczema flare-up of air-exposed rather than covered skin areas occurred. In grass pollen–exposed subjects a significantly higher increase in CCL17, CCL22, and IL-4 serum levels was observed. Conclusions This study demonstrates that controlled exposure to airborne allergens of patients with a so-called extrinsic IgE-mediated form of AD induced a worsening of cutaneous symptoms.
-
anti il 5 recombinant humanized monoclonal antibody mepolizumab for the treatment of atopic dermatitis
Allergy, 2005Co-Authors: J. M. Oldhoff, Ulf Darsow, T. Werfel, K. Katzer, J. Laifaoui, Sabine Gisela Plötz, Edward F. Knol, A Wulf, Dirkjan Hijnen, Alexander KappAbstract:BACKGROUND: Eosinophils may play an important role in the pathogenesis of atopic dermatitis (AD). Interleukin-5 is essential for eosinophil growth, differentiation and migration. A monoclonal antibody to human interleukin-5 (mepolizumab) was developed for atopic diseases. This study was designed to study the effect of mepolizumab in AD. METHODS: Two single doses of 750 mg mepolizumab, given 1 week apart, were studied in patients with moderate to severe AD using a randomized, placebo-controlled parallel group design. The primary endpoint of 'success' to treatment was defined as the percentage of patients with at least 'marked improvement' after 2 weeks as assessed by the Physician's Global Assessment of Improvement (PGA). Furthermore, SCORing AD (SCORAD), pruritus scoring, number of blood eosinophils and serum thymus and activation-regulated chemokine (TARC) values served as secondary endpoints. Fluticasone propionate cream 0.05%, once daily could be used as rescue medication from day 16 if no improvement was recorded. RESULTS: Eighteen patients received mepolizumab and 22 placebo treatment. Peripheral blood eosinophil numbers were significantly reduced in the treatment group compared with placebo (P < 0.05). No clinical success was reached by PGA assessment (P = 0.115), SCORAD (P = 0.293), pruritus scoring and TARC values in the mepolizumab-treated group compared with placebo. However, modest improvement (<50% improvement) assessed by PGA was scored significantly more in the mepolizumab-treated group compared with placebo (P < 0.05). CONCLUSION: Two single doses of 750 mg mepolizumab did not result in clinical success in patients with AD, despite a significant decrease in peripheral blood eosinophils.
-
anti il 5 recombinant humanized monoclonal antibody mepolizumab for the treatment of atopic dermatitis
Allergy, 2005Co-Authors: J. M. Oldhoff, Ulf Darsow, T. Werfel, K. Katzer, J. Laifaoui, Sabine Gisela Plötz, Edward F. Knol, A Wulf, Dirkjan Hijnen, Alexander KappAbstract:Background: Eosinophils may play an important role in the pathogenesis of atopic dermatitis (AD). Interleukin-5 is essential for eosinophil growth, differentiation and migration. A monoclonal antibody to human interleukin-5 (mepolizumab) was developed for atopic diseases. This study was designed to study the effect of mepolizumab in AD. Methods: Two single doses of 750 mg mepolizumab, given 1 week apart, were studied in patients with moderate to severe AD using a randomized, placebo-controlled parallel group design. The primary endpoint of ‘success’ to treatment was defined as the percentage of patients with at least ‘marked improvement’ after 2 weeks as assessed by the Physician's Global Assessment of Improvement (PGA). Furthermore, SCORing AD (SCORAD), pruritus scoring, number of blood eosinophils and serum thymus and activation-regulated chemokine (TARC) values served as secondary endpoints. Fluticason propionate cream 0.05%, once daily could be used as rescue medication from day 16 if no improvement was recorded. Results: Eighteen patients received mepolizumab and 22 placebo treatment. Peripheral blood eosinophil numbers were significantly reduced in the treatment group compared with placebo (P < 0.05). No clinical success was reached by PGA assessment (P = 0.115), SCORAD (P = 0.293), pruritus scoring and TARC values in the mepolizumab-treated group compared with placebo. However, modest improvement (<50% improvement) assessed by PGA was scored significantly more in the mepolizumab-treated group compared with placebo (P < 0.05). Conclusion: Two single doses of 750 mg mepolizumab did not result in clinical success in patients with AD, despite a significant decrease in peripheral blood eosinophils.
Rasmus Wernersson - One of the best experts on this subject based on the ideXlab platform.
-
A scored human protein-protein interaction network to catalyze genomic interpretation.
Nature methods, 2016Co-Authors: Rasmus Wernersson, Rasmus B. Hansen, Johnathan Mercer, Greg Slodkowicz, Kristoffer Rapacki, Heiko Horn, Olga Rigina, Christopher T Workman, Hans H. StærfeldtAbstract:Genome-scale human protein-protein interaction networks are critical to understanding cell biology and interpreting genomic data, but challenging to produce experimentally. Through data integration and quality control, we provide a scored human protein-protein interaction network (InWeb_InBioMap, or InWeb_IM) with severalfold more interactions (>500,000) and better functional biological relevance than comparable resources. We illustrate that InWeb_InBioMap enables functional interpretation of >4,700 cancer genomes and genes involved in autism.
-
A scored human protein-protein interaction network to catalyze genomic interpretation
Nature Methods, 2016Co-Authors: Taibo Li, Rasmus B. Hansen, Johnathan Mercer, Greg Slodkowicz, Kristoffer Rapacki, Heiko Horn, Olga Rigina, Rasmus Wernersson, Christopher T Workman, Hans H. StærfeldtAbstract:Human protein-protein interaction networks are critical to understanding cell biology and interpreting genetic and genomic data, but are challenging to produce in individual large-scale experiments. We describe a general computational framework that through data integration and quality control provides a scored human protein-protein interaction network (InWeb\_IM). Juxtaposed with five comparable resources, InWeb\_IM has 2.8 times more interactions (~585K) and a superior functional signal showing that the added interactions reflect real cellular biology. InWeb_IM is a versatile resource for accurate and cost-efficient functional interpretation of massive genomic datasets illustrated by annotating candidate genes from >4,700 cancer genomes and genes involved in neuropsychiatric diseases.
J. M. Oldhoff - One of the best experts on this subject based on the ideXlab platform.
-
anti il 5 recombinant humanized monoclonal antibody mepolizumab for the treatment of atopic dermatitis
Allergy, 2005Co-Authors: J. M. Oldhoff, Ulf Darsow, T. Werfel, K. Katzer, J. Laifaoui, Sabine Gisela Plötz, Edward F. Knol, A Wulf, Dirkjan Hijnen, Alexander KappAbstract:BACKGROUND: Eosinophils may play an important role in the pathogenesis of atopic dermatitis (AD). Interleukin-5 is essential for eosinophil growth, differentiation and migration. A monoclonal antibody to human interleukin-5 (mepolizumab) was developed for atopic diseases. This study was designed to study the effect of mepolizumab in AD. METHODS: Two single doses of 750 mg mepolizumab, given 1 week apart, were studied in patients with moderate to severe AD using a randomized, placebo-controlled parallel group design. The primary endpoint of 'success' to treatment was defined as the percentage of patients with at least 'marked improvement' after 2 weeks as assessed by the Physician's Global Assessment of Improvement (PGA). Furthermore, SCORing AD (SCORAD), pruritus scoring, number of blood eosinophils and serum thymus and activation-regulated chemokine (TARC) values served as secondary endpoints. Fluticasone propionate cream 0.05%, once daily could be used as rescue medication from day 16 if no improvement was recorded. RESULTS: Eighteen patients received mepolizumab and 22 placebo treatment. Peripheral blood eosinophil numbers were significantly reduced in the treatment group compared with placebo (P < 0.05). No clinical success was reached by PGA assessment (P = 0.115), SCORAD (P = 0.293), pruritus scoring and TARC values in the mepolizumab-treated group compared with placebo. However, modest improvement (<50% improvement) assessed by PGA was scored significantly more in the mepolizumab-treated group compared with placebo (P < 0.05). CONCLUSION: Two single doses of 750 mg mepolizumab did not result in clinical success in patients with AD, despite a significant decrease in peripheral blood eosinophils.
-
anti il 5 recombinant humanized monoclonal antibody mepolizumab for the treatment of atopic dermatitis
Allergy, 2005Co-Authors: J. M. Oldhoff, Ulf Darsow, T. Werfel, K. Katzer, J. Laifaoui, Sabine Gisela Plötz, Edward F. Knol, A Wulf, Dirkjan Hijnen, Alexander KappAbstract:Background: Eosinophils may play an important role in the pathogenesis of atopic dermatitis (AD). Interleukin-5 is essential for eosinophil growth, differentiation and migration. A monoclonal antibody to human interleukin-5 (mepolizumab) was developed for atopic diseases. This study was designed to study the effect of mepolizumab in AD. Methods: Two single doses of 750 mg mepolizumab, given 1 week apart, were studied in patients with moderate to severe AD using a randomized, placebo-controlled parallel group design. The primary endpoint of ‘success’ to treatment was defined as the percentage of patients with at least ‘marked improvement’ after 2 weeks as assessed by the Physician's Global Assessment of Improvement (PGA). Furthermore, SCORing AD (SCORAD), pruritus scoring, number of blood eosinophils and serum thymus and activation-regulated chemokine (TARC) values served as secondary endpoints. Fluticason propionate cream 0.05%, once daily could be used as rescue medication from day 16 if no improvement was recorded. Results: Eighteen patients received mepolizumab and 22 placebo treatment. Peripheral blood eosinophil numbers were significantly reduced in the treatment group compared with placebo (P < 0.05). No clinical success was reached by PGA assessment (P = 0.115), SCORAD (P = 0.293), pruritus scoring and TARC values in the mepolizumab-treated group compared with placebo. However, modest improvement (<50% improvement) assessed by PGA was scored significantly more in the mepolizumab-treated group compared with placebo (P < 0.05). Conclusion: Two single doses of 750 mg mepolizumab did not result in clinical success in patients with AD, despite a significant decrease in peripheral blood eosinophils.
Olga Rigina - One of the best experts on this subject based on the ideXlab platform.
-
A scored human protein-protein interaction network to catalyze genomic interpretation.
Nature methods, 2016Co-Authors: Rasmus Wernersson, Rasmus B. Hansen, Johnathan Mercer, Greg Slodkowicz, Kristoffer Rapacki, Heiko Horn, Olga Rigina, Christopher T Workman, Hans H. StærfeldtAbstract:Genome-scale human protein-protein interaction networks are critical to understanding cell biology and interpreting genomic data, but challenging to produce experimentally. Through data integration and quality control, we provide a scored human protein-protein interaction network (InWeb_InBioMap, or InWeb_IM) with severalfold more interactions (>500,000) and better functional biological relevance than comparable resources. We illustrate that InWeb_InBioMap enables functional interpretation of >4,700 cancer genomes and genes involved in autism.
-
A scored human protein-protein interaction network to catalyze genomic interpretation
Nature Methods, 2016Co-Authors: Taibo Li, Rasmus B. Hansen, Johnathan Mercer, Greg Slodkowicz, Kristoffer Rapacki, Heiko Horn, Olga Rigina, Rasmus Wernersson, Christopher T Workman, Hans H. StærfeldtAbstract:Human protein-protein interaction networks are critical to understanding cell biology and interpreting genetic and genomic data, but are challenging to produce in individual large-scale experiments. We describe a general computational framework that through data integration and quality control provides a scored human protein-protein interaction network (InWeb\_IM). Juxtaposed with five comparable resources, InWeb\_IM has 2.8 times more interactions (~585K) and a superior functional signal showing that the added interactions reflect real cellular biology. InWeb_IM is a versatile resource for accurate and cost-efficient functional interpretation of massive genomic datasets illustrated by annotating candidate genes from >4,700 cancer genomes and genes involved in neuropsychiatric diseases.